Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2002 2
2003 4
2004 3
2005 4
2007 2
2008 2
2009 1
2010 4
2011 1
2012 3
2013 3
2014 4
2016 1
2017 1
2018 3
2019 3
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
Reck M, Barlesi F, Yang JC, Westeel V, Felip E, Özgüroğlu M, Dols MC, Sullivan R, Kowalski DM, Andric Z, Lee DH, Sezer A, Hu P, Wang X, von Heydebreck A, Jacob N, Mehr KT, Park K. Reck M, et al. Among authors: von heydebreck a. J Thorac Oncol. 2024 Feb;19(2):297-313. doi: 10.1016/j.jtho.2023.09.1445. Epub 2023 Sep 24. J Thorac Oncol. 2024. PMID: 37748693 Free article. Clinical Trial.
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, von Heydebreck A, Güzel G, Nghiem P. D'Angelo SP, et al. Among authors: von heydebreck a. ESMO Open. 2024 May;9(5):103461. doi: 10.1016/j.esmoop.2024.103461. Epub 2024 May 13. ESMO Open. 2024. PMID: 38744102 Free PMC article. Clinical Trial.
Transcription profiling of renal cell carcinoma.
Huber W, Boer JM, von Heydebreck A, Gunawan B, Vingron M, Füzesi L, Poustka A, Sültmann H. Huber W, et al. Among authors: von heydebreck a. Verh Dtsch Ges Pathol. 2002;86:153-64. Verh Dtsch Ges Pathol. 2002. PMID: 12647365 Review.
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab.
Terranova N, French J, Dai H, Wiens M, Khandelwal A, Ruiz-Garcia A, Manitz J, von Heydebreck A, Ruisi M, Chin K, Girard P, Venkatakrishnan K. Terranova N, et al. Among authors: von heydebreck a. CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):333-347. doi: 10.1002/psp4.12754. Epub 2022 Jan 19. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34971492 Free PMC article. Clinical Trial.
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL. Disis ML, et al. Among authors: von heydebreck a. JAMA Oncol. 2019 Mar 1;5(3):393-401. doi: 10.1001/jamaoncol.2018.6258. JAMA Oncol. 2019. PMID: 30676622 Free PMC article. Clinical Trial.
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.
Keilholz U, Mehnert JM, Bauer S, Bourgeois H, Patel MR, Gravenor D, Nemunaitis JJ, Taylor MH, Wyrwicz L, Lee KW, Kasturi V, Chin K, von Heydebreck A, Gulley JL. Keilholz U, et al. Among authors: von heydebreck a. J Immunother Cancer. 2019 Jan 16;7(1):12. doi: 10.1186/s40425-018-0459-y. J Immunother Cancer. 2019. PMID: 30651126 Free PMC article. Clinical Trial.
42 results